Coffee consumption after myocardial infarction and risk of cardiovascular mortality: a prospective analysis in the Alpha Omega Cohort

• Published in: The American journal of clinical nutrition Vol. 106; no. 4; pp. 1113 - 1120
• Main Authors: van Dongen, Laura H, Mölenberg, Famke JM, Soedamah-Muthu, Sabita S, Kromhout, Daan, Geleijnse, Johanna M
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.10.2017; American Society for Clinical Nutrition, Inc; American Society for Nutrition
• Subjects: Additives; Aged; Beverages; Caffeine - pharmacology; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - mortality; Cause of Death; Coffea; Coffee; Consumption; Coronary artery disease; Cups; Diet; Fatalities; Female; Follow-Up Studies; Heart attacks; Heart diseases; Humans; Ischemia; Ischemic heart disease; Life Style; Male; Middle Aged; Mortality; Myocardial infarction; Myocardial Infarction - complications; Myocardial infarction patients; Myocardial Ischemia - mortality; Netherlands; Nutrition Surveys; Nutritional Epidemiology and Public Health; Patients; Population studies; Proportional Hazards Models; Prospective cohort study; Prospective Studies; Risk; Risk Factors; Surveys and Questionnaires; Netherlands; myocardial infarction patients; ischemic heart disease; mortality; cardiovascular disease; prospective cohort study; coffee
• ISSN: 0002-9165; 1938-3207
• DOI: 10.3945/ajcn.117.153338

Abstract Background: Consumption of coffee, one of the most popular beverages around the world, has been associated with a lower risk of cardiovascular and all-cause mortality in population-based studies. However, little is known about these associations in patient populations. Objective: This prospective study aimed to examine the consumption of caffeinated and decaffeinated coffee in relation to cardiovascular disease (CVD) mortality, ischemic heart disease (IHD) mortality, and all-cause mortality in patients with a prior myocardial infarction (MI). Design: We included 4365 Dutch patients from the Alpha Omega Cohort who were aged 60–80 y (21% female) and had experienced an MI <10 y before study enrollment. At baseline (2002–2006), dietary data including coffee consumption over the past month was collected with a 203-item validated food-frequency questionnaire. Causes of death were monitored until 1 January 2013. HRs for mortality in categories of coffee consumption were obtained from multivariable Cox proportional hazard models, adjusting for lifestyle and dietary factors. Results: Most patients (96%) drank coffee, and the median total coffee intake was 375 mL/d (∼3 cups/d). During a median follow-up of 7.1 y, a total of 945 deaths occurred, including 396 CVD-related and 266 IHD-related deaths. Coffee consumption was inversely associated with CVD mortality, with HRs of 0.69 (95% CI: 0.54, 0.89) for >2–4 cups/d and 0.72 (0.55, 0.95) for >4 cups/d, compared with 0–2 cups/d. Corresponding HRs were 0.77 (95% CI: 0.57, 1.05) and 0.68 (95% CI: 0.48, 0.95) for IHD mortality and 0.84 (95% CI: 0.71, 1.00) and 0.82 (95% CI: 0.68, 0.98) for all-cause mortality, respectively. Similar associations were found for decaffeinated coffee and for coffee with additives. Conclusion: Drinking coffee, either caffeinated or decaffeinated, may lower the risk of CVD and IHD mortality in patients with a prior MI. This study was registered at clinicaltrials.gov as NCT03192410.